NCT00403039View on ClinicalTrials.gov

Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

PHASE1CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Retinal Vein Occlusion

Interventions

DRUG

Ranibizumab (Lucentis )

Trial Locations (1)

10022

Vitreous Retina Macula Consultants of New York, P.C., New York

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Vitreous -Retina- Macula Consultants of New York

OTHER

NCT00403039 - Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema | Biotech Hunter | Biotech Hunter